SCHEMBL898422

SCHEMBL898422

CS(=O)(=O)c1ccc(N)c(N)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PD P11413 1/20 0.64
IDE P14735 1/20 0.64
ALDH1A1 P00352 4/20 0.57
PKM P14618 2/20 0.57
GAA P10253 2/20 0.57
MAPT P10636 2/20 0.57
KDM4E B2RXH2 1/20 0.57
MEN1 O00255 1/20 0.57
RAB9A P51151 1/20 0.57
KMT2A Q03164 1/20 0.57
HTR6 P50406 1/20 0.57
LMNA P02545 1/20 0.46
ENPP2 Q13822 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CA12 O43570 5/20 0.43
CA1 P00915 5/20 0.43
CA2 P00918 5/20 0.43
CA9 Q16790 5/20 0.43
CA4 P22748 4/20 0.43
CA6 P23280 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8320176 0.83 MEN1 (0.56) G6PDIDEALDH1A1PKMGAA
SCHEMBL1368132 0.82 G6PD (0.55) G6PDIDEALDH1A1GAAMAPT
SCHEMBL2908276 0.82 G6PD (0.60) G6PDIDEALDH1A1PKMGAA
SCHEMBL4639254 0.82 G6PD (0.60) G6PDIDEALDH1A1PKMGAA
SCHEMBL1371001 0.80 G6PD (0.53) G6PDIDEPKMGAAMAPT
SCHEMBL1371008 0.80 G6PD (0.53) G6PDIDEALDH1A1CA12CA1
SCHEMBL1370002 0.80 LMNA (0.55) G6PDIDEALDH1A1PKMMAPT
SCHEMBL6932811 0.80 G6PD (0.58) G6PDIDEALDH1A1PKMGAA
SCHEMBL303829 0.80 CA1 (0.68) G6PDIDEALDH1A1MAPTLMNA
SCHEMBL221279 0.80 CA1 (0.68) G6PDIDEALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795340-B2 Compositon sensitive to UV-C radiation and UV-C sterilization or disinfection dosimeter TERRAGENE S.A. (AR) 2023-10-24 US claimed
EP-3964554-A1 COMPOSITON SENSITIVE TO UV-C RADIATION AND UV-C STERILIZATION OR DISINFECTION DOSIMETER Terragene LLC (US) 2022-03-09 EP claimed
EP-1828210-A1 CHEMICAL COMPOSITIONS FOR AUTHENTICATABLE POLYMERS AND ARTICLES, AND AUTHENTICATION METHODS THEREOF General Electric Company (US) 2007-09-05 EP claimed
US-7230113-B2 Chemical compositions for authenticatable polymers and articles, and authentication methods thereof GENERAL ELECTRIC COMPANY (US) 2007-06-12 US claimed
WO-2006065541-A1 CHEMICAL COMPOSITIONS FOR AUTHENTICATABLE POLYMERS AND ARTICLES, AND AUTHENTICATION METHODS THEREOF GENERAL ELECTRIC COMPANY (US) 2006-06-22 WO claimed
US-20060135658-A1 Chemical compositions for authenticatable polymers and articles, and authentication methods thereof SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2006-06-22 US claimed
EP-4702017-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2026-03-04 EP disclosed
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC 2025-02-06 US disclosed
US-20240343728-A1 COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. 2024-10-17 US disclosed
US-12029744-B2 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors RIBOSCIENCE LLC (US) 2024-07-09 US disclosed
CN-118159534-A Compounds that inhibit PI3K isoform alpha and methods for treating cancer 蝎子疗法股份有限公司 2024-06-07 CN disclosed
EP-4363414-A1 COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER Scorpion Therapeutics, Inc. (US) 2024-05-08 EP disclosed
CN-113166156-B Tyrosine kinase inhibitors, compositions and methods 贝达药业股份有限公司 2024-02-27 CN disclosed
US-4018790-A VIRICIDES ELI LILLY AND COMPANY (US) 1977-04-19 US disclosed
US-4011341-A HERBICIDES ELI LILLY AND COMPANY (US) 1977-03-08 US disclosed
US-4008225-A Process for the manufacture of bis-azomethine metal complex colorants CIBA-GEIGY CORPORATION (US) 1977-02-15 US disclosed
US-4002640-A ANTIFUNGAL AGENTS SYNTEX (U.S.A.) INC. (US) 1977-01-11 US disclosed
US-4000135-A IRON TETRAAZANNULENES AS CATALYSTS BASF AKTIENGESELLSCHAFT (DT) 1976-12-28 US disclosed
US-3963708-A Bis-azomethine metal complex colorants from hydroxycoumarin derivatives or hydroxychromone derivatives CIBA-GEIGY CORPORATION (US) 1976-06-15 US disclosed
US-3939194-A Bis-2-azomethine pigments, process for their manufacture and their use CIBA-GEIGY CORPORATION (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135658-A1 Chemical compositions for authenticatable polymers and articles, and authentication methods thereof H1-4, BICRA, PBRM1 G6PD 4374/4885IDE 4204/4885ALDH1A1 2243/4885
US-20240343728-A1 COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER PIK3CA, PIK3CD, PIK3CG G6PD 256/4885IDE 648/4885ALDH1A1 1133/4885
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS ENPP1, ENPP3, SMPD1 G6PD 84/4885IDE 630/4885ALDH1A1 874/4885
US-12029744-B2 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors ENPP1, ENPP3, SMPD1 G6PD 82/4885IDE 635/4885ALDH1A1 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.